Filed by Rite Aid Corporation
Pursuant to Rule 425
under the Securities Act of 1933
and deemed filed pursuant
to Rule 14a-12
under the Securities
and Exchange Act of 1934
Subject Company: Rite
Aid Corporation
Commission File No. for
the Related Registration Statement: 001-05742
On April 18, 2018, Rite Aid Corporation
(“Rite Aid”) filed a Current Report on Form 8-K with the following information:
As previously disclosed, on February 18,
2018, Rite Aid entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Albertsons Companies, Inc.,
a Delaware corporation (“Albertsons”), Ranch Acquisition II LLC, a Delaware limited liability company and a wholly-owned
direct subsidiary of Albertsons (“Merger Sub II”), and Ranch Acquisition Corp., a Delaware corporation and a wholly-owned
direct subsidiary of Merger Sub II (“Merger Sub”). Pursuant to the terms and subject to the conditions set forth in
the Merger Agreement, (i) Merger Sub will merge with and into Rite Aid (the “Merger”), with Rite Aid surviving the
Merger as a wholly-owned direct subsidiary of Merger Sub II (the “Surviving Corporation”), and (ii) immediately following
the Merger, the Surviving Corporation will merge with and into Merger Sub II (the “Subsequent Merger”), with Merger
Sub II surviving the Subsequent Merger as a wholly-owned direct subsidiary of Albertsons. Consummation of the Merger remains subject
to various closing conditions, including but not limited to the approval of the Merger Agreement by holders of a majority of the
outstanding shares of Rite Aid stock entitled to vote on the Merger.
In connection with Albertsons’ efforts
to obtain debt financing to fund a portion of the amount necessary to complete the Merger and pay related fees in connection with
the Merger and related transactions, Rite Aid and Albertsons are presenting to prospective lenders certain information regarding
the combined company. Rite Aid is furnishing this Current Report on Form 8-K to disclose certain information relating to Rite Aid
that is being presented to prospective lenders.
The table below contains a reconciliation
of Adjusted EBITDA to net income for the periods presented above.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
|
|
|
|
Thirteen
weeks ended
|
|
|
Thirteen
weeks ended
|
|
|
Thirteen
weeks ended
|
|
|
Thirteen
weeks ended
|
|
|
Fifty-two
weeks ended
|
|
|
|
May
30, 2015
|
|
|
August
29, 2015
|
|
|
November
28, 2015
|
|
|
February
27, 2016
|
|
|
February
27, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
8,035
|
|
|
$
|
840
|
|
|
$
|
35,137
|
|
|
$
|
58,076
|
|
|
$
|
102,088
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
57,765
|
|
|
|
49,555
|
|
|
|
41,014
|
|
|
|
37,798
|
|
|
|
186,132
|
|
Income tax expense
|
|
|
5,241
|
|
|
|
900
|
|
|
|
28,499
|
|
|
|
14,872
|
|
|
|
49,512
|
|
Depreciation and amortization
|
|
|
73,689
|
|
|
|
91,501
|
|
|
|
98,488
|
|
|
|
97,456
|
|
|
|
361,134
|
|
LIFO charge (credit)
|
|
|
3,637
|
|
|
|
3,636
|
|
|
|
3,634
|
|
|
|
(3,015
|
)
|
|
|
7,892
|
|
Lease termination and impairment
charges
|
|
|
5,019
|
|
|
|
9,637
|
|
|
|
6,951
|
|
|
|
18,870
|
|
|
|
40,477
|
|
Loss on Debt Modification
|
|
|
-
|
|
|
|
33,205
|
|
|
|
-
|
|
|
|
-
|
|
|
|
33,205
|
|
Walgreens Boots Alliance merger
termination fee
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Gain on stores sold to Walgreens
Boots Alliance
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonrecurring Acquisition
|
|
|
2,084
|
|
|
|
10,381
|
|
|
|
10,077
|
|
|
|
5,686
|
|
|
|
28,228
|
|
Dead Deal Expense
|
|
|
1,069
|
|
|
|
144
|
|
|
|
174
|
|
|
|
429
|
|
|
|
1,816
|
|
(Gain) loss on FA
|
|
|
(258
|
)
|
|
|
(694
|
)
|
|
|
2,128
|
|
|
|
(1,782
|
)
|
|
|
(606
|
)
|
Liquidation Charges
|
|
|
434
|
|
|
|
664
|
|
|
|
617
|
|
|
|
270
|
|
|
|
1,985
|
|
Non-Cash Stock and Other
|
|
|
7,370
|
|
|
|
8,831
|
|
|
|
10,328
|
|
|
|
11,419
|
|
|
|
37,948
|
|
Non-Recurring Severance
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Wellness
Deferral
|
|
|
7,901
|
|
|
|
(2,062
|
)
|
|
|
(9,701
|
)
|
|
|
3,318
|
|
|
|
(544
|
)
|
Adjusted
EBITDA - continuing operations
|
|
$
|
171,986
|
|
|
$
|
206,538
|
|
|
$
|
227,346
|
|
|
$
|
243,397
|
|
|
$
|
849,267
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustment to reflect full
TSA fees
|
|
|
24,000
|
|
|
|
24,000
|
|
|
|
24,000
|
|
|
|
24,000
|
|
|
|
96,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro-forma Adjusted EBITDA
|
|
$
|
195,986
|
|
|
$
|
230,538
|
|
|
$
|
251,346
|
|
|
$
|
267,397
|
|
|
$
|
945,267
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
|
|
|
|
Thirteen weeks ended
|
|
|
Thirteen weeks ended
|
|
|
Thirteen weeks ended
|
|
|
Fourteen weeks ended
|
|
|
Fifty-three weeks ended
|
|
|
|
May 28, 2016
|
|
|
August 27, 2016
|
|
|
November 26, 2016
|
|
|
March 4, 2017
|
|
|
March 4, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of net (loss) income to adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income
|
|
$
|
(512
|
)
|
|
$
|
6,036
|
|
|
$
|
23,610
|
|
|
$
|
(25,054
|
)
|
|
$
|
4,080
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
46,668
|
|
|
|
49,703
|
|
|
|
50,303
|
|
|
|
53,391
|
|
|
|
200,065
|
|
Income tax (benefit) expense
|
|
|
(3,021
|
)
|
|
|
3,879
|
|
|
|
(4,682
|
)
|
|
|
48,262
|
|
|
|
44,438
|
|
Depreciation and amortization
|
|
|
100,281
|
|
|
|
102,225
|
|
|
|
101,953
|
|
|
|
102,906
|
|
|
|
407,366
|
|
LIFO charge (credit)
|
|
|
8,468
|
|
|
|
8,426
|
|
|
|
8,373
|
|
|
|
(28,987
|
)
|
|
|
(3,721
|
)
|
Lease termination and impairment charges
|
|
|
5,778
|
|
|
|
7,226
|
|
|
|
7,199
|
|
|
|
25,575
|
|
|
|
45,778
|
|
Loss on Debt Modification
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Walgreens Boots Alliance merger termination fee
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Gain on stores sold to Walgreens Boots Alliance
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonrecurring Acquisition
|
|
|
2,756
|
|
|
|
1,402
|
|
|
|
1,964
|
|
|
|
7,944
|
|
|
|
14,066
|
|
Dead Deal Expense
|
|
|
446
|
|
|
|
816
|
|
|
|
164
|
|
|
|
462
|
|
|
|
1,888
|
|
(Gain) loss on FA
|
|
|
397
|
|
|
|
(560
|
)
|
|
|
(225
|
)
|
|
|
(6,261
|
)
|
|
|
(6,649
|
)
|
Liquidation Charges
|
|
|
542
|
|
|
|
2,771
|
|
|
|
1,533
|
|
|
|
1,079
|
|
|
|
5,925
|
|
Non-Cash Stock and Other
|
|
|
11,144
|
|
|
|
12,552
|
|
|
|
13,070
|
|
|
|
(13,284
|
)
|
|
|
23,482
|
|
Non-Recurring Severance
|
|
|
4,485
|
|
|
|
1,772
|
|
|
|
2,047
|
|
|
|
2,866
|
|
|
|
11,170
|
|
Wellness Deferral
|
|
|
8,059
|
|
|
|
(592
|
)
|
|
|
(13,976
|
)
|
|
|
(1,328
|
)
|
|
|
(7,837
|
)
|
Adjusted EBITDA - continuing operations
|
|
$
|
185,491
|
|
|
$
|
195,656
|
|
|
$
|
191,333
|
|
|
$
|
167,571
|
|
|
$
|
740,051
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustment to reflect full TSA fees
|
|
|
24,000
|
|
|
|
24,000
|
|
|
|
24,000
|
|
|
|
24,000
|
|
|
|
96,000
|
|
Adjustment for 53rd week
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10,800
|
)
|
|
|
(10,800
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro-forma Adjusted EBITDA
|
|
$
|
209,491
|
|
|
$
|
219,656
|
|
|
$
|
215,333
|
|
|
$
|
180,771
|
|
|
$
|
825,251
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
|
|
|
|
Thirteen weeks ended
|
|
|
Thirteen weeks ended
|
|
|
Thirteen weeks ended
|
|
|
Thirteen weeks ended
|
|
|
Fifty-two weeks ended
|
|
|
|
June 3, 2017
|
|
|
September 2, 2017
|
|
|
December 2, 2017
|
|
|
March 3, 2018
|
|
|
March 3, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of net (loss) income to adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income
|
|
$
|
(36,037
|
)
|
|
$
|
188,360
|
|
|
$
|
(18,182
|
)
|
|
$
|
(483,673
|
)
|
|
$
|
(349,532
|
)
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
51,000
|
|
|
|
50,857
|
|
|
|
50,308
|
|
|
|
50,603
|
|
|
|
202,768
|
|
Income tax (benefit) expense
|
|
|
(12,121
|
)
|
|
|
117,450
|
|
|
|
(16,061
|
)
|
|
|
216,719
|
|
|
|
305,987
|
|
Depreciation and amortization
|
|
|
101,029
|
|
|
|
95,655
|
|
|
|
95,764
|
|
|
|
93,609
|
|
|
|
386,057
|
|
LIFO charge (credit)
|
|
|
10,173
|
|
|
|
3,436
|
|
|
|
6,784
|
|
|
|
(49,220
|
)
|
|
|
(28,827
|
)
|
Lease termination and impairment charges
|
|
|
4,038
|
|
|
|
3,113
|
|
|
|
3,939
|
|
|
|
47,675
|
|
|
|
58,765
|
|
Goodwill impairment
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
261,727
|
|
|
|
261,727
|
|
Loss on Debt Modification
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Walgreens Boots Alliance merger termination fee
|
|
|
-
|
|
|
|
(325,000
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(325,000
|
)
|
Gain on stores sold to Walgreens Boots Alliance
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonrecurring Acquisition
|
|
|
1,217
|
|
|
|
582
|
|
|
|
(5,022
|
)
|
|
|
4,743
|
|
|
|
1,520
|
|
Dead Deal Expense
|
|
|
388
|
|
|
|
116
|
|
|
|
1,055
|
|
|
|
1,786
|
|
|
|
3,345
|
|
(Gain) loss on FA
|
|
|
(5,877
|
)
|
|
|
(14,951
|
)
|
|
|
205
|
|
|
|
(5,249
|
)
|
|
|
(25,872
|
)
|
Liquidation Charges
|
|
|
2,418
|
|
|
|
1,348
|
|
|
|
2,055
|
|
|
|
1,765
|
|
|
|
7,586
|
|
Non-Cash Stock and Other
|
|
|
9,038
|
|
|
|
6,324
|
|
|
|
7,187
|
|
|
|
3,244
|
|
|
|
25,793
|
|
Non-Recurring Severance
|
|
|
784
|
|
|
|
9,612
|
|
|
|
14,030
|
|
|
|
11,111
|
|
|
|
35,537
|
|
Wellness Deferral
|
|
|
9,914
|
|
|
|
375
|
|
|
|
(12,813
|
)
|
|
|
2,564
|
|
|
|
40
|
|
Adjusted EBITDA - continuing operations
|
|
$
|
135,964
|
|
|
$
|
137,277
|
|
|
$
|
129,249
|
|
|
$
|
157,404
|
|
|
$
|
559,894
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustment to reflect full TSA fees
|
|
|
24,000
|
|
|
|
24,000
|
|
|
|
23,800
|
|
|
|
15,800
|
|
|
$
|
87,600
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro-forma Adjusted EBITDA
|
|
$
|
159,964
|
|
|
$
|
161,277
|
|
|
$
|
153,049
|
|
|
$
|
173,204
|
|
|
$
|
647,494
|
|
Rite Aid believes Adjusted EBITDA serves
as an appropriate measure in evaluating the performance of its business and helps its analysts and investors to evaluate ongoing
results of operations, when considered alongside other GAAP measures, such as net income, operating income and gross profit. Rite
Aid defines Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization,
LIFO adjustments, charges or credits for facility closing and impairment, inventory write-downs related to store closings, debt
retirements, the previously received Walgreens Boots Alliance, Inc. (“WBA”) merger termination fee, and other items
(including stock-based compensation expense, merger and acquisition-related costs, severance and costs related to distribution
center closures, gain or loss on sale of assets and revenue deferrals related to Rite Aid’s customer loyalty program). Rite
Aid references this non-GAAP financial measure frequently in its decision-making because it provides supplemental information that
facilitates internal comparisons to historical periods and external comparisons to competitors. In addition, incentive compensation
is based in part on Adjusted EBITDA and Rite Aid bases certain of its forward-looking estimates and budgets on Adjusted EBITDA.
Rite Aid defines Pro Forma Adjusted EBITDA
as Adjusted EBITDA plus the fees that would have been earned under the Transition Services Agreement (the “TSA”) with
WBA for the relevant period, and in order to improve comparability, Pro Forma Adjusted EBITDA further adjusts results so that periods
contain the same number of weeks.
Adjusted EBITDA and Pro Forma Adjusted EBITDA
should not be considered in isolation from, and are not intended to represent alternative measures of, operating results or of
cash flows from operating activities, as determined in accordance with GAAP. Rite Aid’s definitions of Adjusted EBITDA and
Pro Forma Adjusted EBITDA may not be comparable to similarly titled measurements reported by other companies or similar terms in
Rite Aid’s debt facilities.
The information being furnished pursuant
to this “Item 7.01 Regulation FD Disclosure” shall not be deemed to be “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section
and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities
Act, or the Exchange Act regardless of any general incorporation language in such filing.
Important Notice Regarding Forward-Looking Statements
This communication contains certain “forward-looking statements”
within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended by the Private Securities
Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the pending merger between
Rite Aid and Albertsons and the transactions contemplated thereby, and the parties perspectives and expectations, are forward looking
statements. Such statements include, but are not limited to, statements regarding the benefits of the proposed merger, anticipated
future financial and operating performance and results, including estimates for growth, and the expected timing of the transactions
contemplated by the merger agreement. The words “expect,” “believe,” “estimate,” “intend,”
“plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees
of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic,
market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those
indicated or anticipated. Such risks and uncertainties include, but are not limited to, risks related to the expected timing and
likelihood of completion of the pending merger, including the risk that the transaction may not close due to one or more closing
conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis
or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction
or required certain conditions, limitations or restrictions in connection with such approvals, or that the required approval of
the merger agreement by the stockholders of Rite Aid was not obtained; risks related to the ability of Albertsons and Rite Aid
to successfully integrate the businesses; the occurrence of any event, change or other circumstances that could give rise to the
termination of the merger agreement (including circumstances requiring Rite Aid to pay Albertsons a termination fee pursuant to
the merger agreement); the risk that there may be a material adverse change of Rite Aid or Albertsons; risks related to disruption
of management time from ongoing business operations due to the proposed transaction; the risk that any announcements relating to
the proposed transaction could have adverse effects on the market price of Rite Aid’s common stock, and the risk that the
proposed transaction and its announcement could have an adverse effect on the ability of Rite Aid to retain customers and retain
and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses
generally; risks related to successfully integrating the businesses of the companies, which may result in the combined company
not operating as effectively and efficiently as expected; the risk that the combined company may be unable to achieve cost-cutting
synergies or it may take longer than expected to achieve those synergies; and risks associated with the financing of the proposed
transaction. A further list and description of risks and uncertainties can be found in Rite Aid’s Annual Report on Form 10-K
for the fiscal year ended March 4, 2017 filed with the Securities and Exchange Commission (“SEC”) and in the registration
statement on Form S-4, as it may be amended, that was filed with the SEC by Albertsons on April 6, 2018 in connection with the
proposed merger, and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should
one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary
materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place
undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and Rite
Aid undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made
except as required by law or applicable regulation. All information regarding Rite Aid assumes completion of Rite Aid’s previously
announced transaction with Walgreens Boots Alliance, Inc. There can be no assurance that the consummation of such transaction will
be completed on a timely basis, if at all. For further information on such transaction, see Rite Aid’s Form 8-K filed with
the SEC on March 5, 2018.
Additional Information and Where to Find It
In connection with the proposed merger involving Rite Aid and
Albertsons, Rite Aid and Albertsons have prepared and Albertsons has filed with the SEC on April 6, 2018 a registration statement
on Form S-4 that includes a proxy statement of Rite Aid that also constitutes a prospectus of Albertsons. The registration statement
is not yet final and will be amended. Rite Aid will mail the proxy statement/prospectus and a proxy card to each stockholder entitled
to vote at the special meeting relating to the proposed merger. Rite Aid and Albertsons also plan to file other relevant documents
with the SEC regarding the proposed merger. INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES
AVAILABLE, AS WELL AS OTHER DOCUMENTS FILED WITH THE SEC, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. RITE AID’S EXISTING
PUBLIC FILINGS WITH THE SEC SHOULD ALSO BE READ, INCLUDING THE RISK FACTORS CONTAINED THEREIN.
Investors and security holders may obtain copies of the Form
S-4, including the proxy statement/prospectus, as well as other filings containing information about Rite Aid, free of charge,
from the SEC’s Web site (www.sec.gov). Investors and security holders may also obtain Rite Aid’s SEC filings in connection
with the transaction, free of charge, from Rite Aid’s Web site (www.RiteAid.com) under the link “Investor Relations”
and then under the tab “SEC Filings,” or by directing a request to Rite Aid, Byron Purcell, Attention: Senior Director,
Treasury Services & Investor Relations. Copies of documents filed with the SEC by Albertsons will be made available, free of
charge, on Albertsons’ website at www.albertsonscompanies.com.
Participants in Solicitation
Rite Aid, Albertsons and their respective directors, executive
officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of Rite
Aid common stock in respect of the proposed transaction. Information regarding Rite Aid’s directors and executive officers
is available in its definitive proxy statement for Rite Aid’s 2017 annual meeting of stockholders filed with the SEC on June
7, 2017, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such definitive proxy statement.
Information about the directors and executive officers of Albertsons is set forth in the registration statement on Form S-4, including
the proxy statement/prospectus, as it may be amended, that has been filed with the SEC on April 6, 2018. Other information regarding
the interests of the participants in the proxy solicitation will be included in the proxy statement/prospectus when it becomes
available. These documents can be obtained free of charge from the sources indicated above.
Non-Solicitation
This communication shall not constitute an offer to sell or
the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements
of Section 10 of the Securities Act of 1933, as amended.
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Sep 2023 to Sep 2024